{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "exchange": "NMS", "shortName": "Prometheus Biosciences, Inc.", "longName": "Prometheus Biosciences, Inc.", "messageBoardId": "finmb_540181722", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "regularMarketChangePercent": -1.0337883, "regularMarketPrice": 192.42, "firstTradeDateMilliseconds": 1615559400000, "priceHint": 2, "fiftyTwoWeekLowChange": 170.11, "fiftyTwoWeekLowChangePercent": 7.624832, "fiftyTwoWeekRange": "22.31 - 197.83", "fiftyTwoWeekHighChange": -5.4100037, "fiftyTwoWeekHighChangePercent": -0.02734673, "fiftyTwoWeekLow": 22.31, "fiftyTwoWeekHigh": 197.83, "earningsTimestamp": 1620936000, "earningsTimestampStart": 1620936000, "earningsTimestampEnd": 1620936000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.5, "epsForward": -4.6, "epsCurrentYear": -3.99, "priceEpsCurrentYear": -48.225563, "sharesOutstanding": 47809500, "bookValue": 14.431, "fiftyDayAverage": 147.3935, "fiftyDayAverageChange": 45.026505, "fiftyDayAverageChangePercent": 0.305485, "twoHundredDayAverage": 93.12813, "twoHundredDayAverageChange": 99.29187, "twoHundredDayAverageChangePercent": 1.0661856, "marketCap": 9199504384, "forwardPE": -41.830437, "priceToBook": 13.333796, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-12", "averageAnalystRating": "2.8 - Hold", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -2.0099945, "regularMarketTime": 1684261160, "regularMarketDayHigh": 193.5, "regularMarketDayRange": "189.76 - 193.5", "regularMarketDayLow": 189.76, "regularMarketVolume": 1291557, "regularMarketPreviousClose": 194.43, "bid": 192.55, "ask": 192.61, "bidSize": 8, "askSize": 9, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 190.63, "averageDailyVolume3Month": 1018313, "averageDailyVolume10Day": 949530, "displayName": "Prometheus Biosciences", "symbol": "RXDX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3050 Science Park Road", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 422 4300", "website": "https://www.prometheusbiosciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.", "fullTimeEmployees": 97, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark C. McKenna", "age": 42, "title": "Pres, CEO & Chairman", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 1325607, "fmt": "1.33M", "longFmt": "1,325,607"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Keith W. Marshall M.B.A., MBA, Ph.D.", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 829452, "fmt": "829.45k", "longFmt": "829,452"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Stenhouse", "age": 55, "title": "Chief Operating Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 807402, "fmt": "807.4k", "longFmt": "807,402"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Olivier  Laurent Ph.D.", "age": 50, "title": "Chief Scientific Officer & Head of R&D", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Noel  Kurdi", "title": "VP of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy K. Andrews Esq.", "age": 43, "title": "Gen. Counsel & Sec.", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nori  Ebersole", "age": 58, "title": "Chief People Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Allison  Luo M.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Thierry  Dervieux DABCC, Ph.d., Pharm.d.", "age": 54, "title": "Chief Devel. Officer of Diagnostics & Medical Laboratory Director", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Doughty", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}